載入...
Objective and subjective measures of dalfampridine efficacy in clinical practice
BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...
Na minha lista:
| 發表在: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6077903/ https://ncbi.nlm.nih.gov/pubmed/30090641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318786742 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|